Have a known hypersensitivity or allergy to biopharmaceutical agents produced in Chinese hamster ovary cells or any component of the atezolizumab and/or bevacizumab formulationsXx_NEWLINE_xXAllergy or hypersensitivity to components of the cobimetinib formulationsXx_NEWLINE_xXThe subject has a history of allergy or intolerance to flucytosineXx_NEWLINE_xXPatients with a history of allergic reaction to irinotecan, cephalosporins or a severe penicillin allergy are not eligibleXx_NEWLINE_xXNo known allergy to aspirinXx_NEWLINE_xXPatients must not have any known allergy or reaction to any component of the durvalumab (MEDI4736) and/or tremelimumab formulationXx_NEWLINE_xXPatients must not have prior history of allergy or known hypersensitivity to nivolumab or ipilimumabXx_NEWLINE_xXNo history of severe hypersensitivity reaction to any monoclonal antibody or allergy to study drug components;Xx_NEWLINE_xXNo known allergy to 5-fluorouracil, oxaliplatin, or leucovorinXx_NEWLINE_xXKnown allergy to boron or excipients in the formulationXx_NEWLINE_xXPatients with known allergy to mitoxantrone, cytarabine, or both etoposide and etoposide phosphate (Etopophos)Xx_NEWLINE_xXThe patient must NOT have a known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulationXx_NEWLINE_xXPatient has history of allergy to any oily drug productsXx_NEWLINE_xXSubject has known contraindication or allergy to both xanthine oxidase inhibitors and rasburicaseXx_NEWLINE_xXPatients with a known or documented anaphylactic reaction or allergy to any of chemotherapy agents used in this protocol, or to antiemetics appropriate for administration in conjunction with protocol-directed therapyXx_NEWLINE_xXKnown allergy to any of the study agentsXx_NEWLINE_xXHistory of allergy to study drug component or history of severe hypersensitivity reaction to any monoclonal antibody.Xx_NEWLINE_xXAllergy or hypersensitivity to cemiplimab or to any of its excipients;Xx_NEWLINE_xXKnown allergy, hypersensitivity or contraindication to components of the FPA144 formulation including polysorbate or to platinum-containing medications, 5-FU, or leucovorinXx_NEWLINE_xXKnown allergy or hypersensitivity to any of the study drugs or their excipients.Xx_NEWLINE_xXHistory of allergy or hypersensitivity to any study drugs or their excipientsXx_NEWLINE_xXHistory of allergy to study drug components or history of severe hypersensitivity reaction of any monoclonal antibodyXx_NEWLINE_xXKnown hypersensitivity or allergy to murine products or any component of the obinutuzumab, rituximab, idasanutlin, or venetoclax formulationXx_NEWLINE_xXAllergy or hypersensitivity to components of the KO-947 formulation, e.g. dextrose, hydroxypropyl beta cyclodextrin, acetic acid, sodium acetate and water for injection.Xx_NEWLINE_xXKnown allergy to both xanthine oxidase inhibitors and rasburicaseXx_NEWLINE_xXHistory of allergy to study drug componentsXx_NEWLINE_xXKnown allergy to eggs, gentamicin, or platinum containing compoundsXx_NEWLINE_xXKnown or suspected allergy to the investigational agent or any agent given in association with this trial.Xx_NEWLINE_xXKnown or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trialXx_NEWLINE_xXKnown allergy to enadenotucirev, nivolumab or their excipientsXx_NEWLINE_xXKnown allergy, hypersensitivity, or contraindication to paclitaxel, docetaxel, or irinotecan or any components used in their preparationXx_NEWLINE_xXKnown allergy to any of the study medications, their analogues, or excipients in the various formulations of any agentXx_NEWLINE_xXAllergy to iodine or gadolinium contrast that cannot be safely controlled with premedicationXx_NEWLINE_xXPatients who have a known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent are not eligibleXx_NEWLINE_xXKnown history of positive serum human anti-drug antibody (ADA), or known allergy to any component of ADCT-301Xx_NEWLINE_xXPrior allergy or adverse reaction to methotrexateXx_NEWLINE_xXPreviously identified allergy or hypersensitivity to components of the cabozantinib formulationsXx_NEWLINE_xXKnown history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)Xx_NEWLINE_xXNo known allergy or adverse reaction (e.g., wound dehiscence) to poly-lactide-co-glycolide (PLG)Xx_NEWLINE_xXKnown allergy to egg products or soy bean oilXx_NEWLINE_xXPreviously identified allergy or hypersensitivity to components of the study treatment formulationsXx_NEWLINE_xXDocumented allergy to DMSO, mouse or bovine proteins, or iron.Xx_NEWLINE_xXHistory of allergy to study treatments or any of its components of the study arm that participant is enrollingXx_NEWLINE_xXKnown allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.Xx_NEWLINE_xXKnown allergy or reaction to any component of either study drug formulationXx_NEWLINE_xXKnown allergy or hypersensitivity to the components of the atezolizumab formulation.Xx_NEWLINE_xXKnown allergy or hypersensitivity to the components of the doxorubicin, cyclophosphamide, carboplatin, or paclitaxel formulations.Xx_NEWLINE_xXKnown allergy or hypersensitivity to liposomal or pegylated G-CSF formulations.Xx_NEWLINE_xXPatients with a history of allergy to the study drug components are excludedXx_NEWLINE_xXKnown sensitivity or allergy to murine products or any component of RO6870810, venetoclax, or rituximab.Xx_NEWLINE_xXAny history of allergy to the study drug componentsXx_NEWLINE_xXKnown allergy to any of the study medications, their analogues, or excipients in the various formulations of any agentXx_NEWLINE_xXKnown allergy or hypersensitivity to the components of the formulations of atezolizumab, nab-paclitaxel, cyclophosphamide, or doxorubicin, filgrastim or pegfilgrastimXx_NEWLINE_xXA history of a severe contrast allergy (i.e. anaphylaxis) not controlled with premedicationXx_NEWLINE_xXKnown allergy/intolerance to soy, phosphatidylcholine or any other constituents of grape seed extractXx_NEWLINE_xXPatients with a latex allergyXx_NEWLINE_xXKnown in tolerance and allergy to cytarabine.Xx_NEWLINE_xXThe patient has a known allergy/history of hypersensitivity reaction to any of the treatment components, including any ingredient used in the formulation of necitumumab, or any other contraindication to one of the administered treatmentsXx_NEWLINE_xXHistory of allergy to study drug componentsXx_NEWLINE_xXPrevious known allergy or intolerance to pembrolizumab or any of its excipientsXx_NEWLINE_xXPrevious exposure or known allergy to Imprime PGG or any of its excipientsXx_NEWLINE_xXKnown allergy or hypersensitivity to any component of the atezolizumab formulationXx_NEWLINE_xXKnown allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.Xx_NEWLINE_xXKnown allergy to xanthine oxidase inhibitors and/or rasburicase for subjects at risk for tumor lysis syndromeXx_NEWLINE_xXKnown allergy to grapes or grape seedXx_NEWLINE_xXHistory of allergy to study drug componentsXx_NEWLINE_xXKnown hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any components of cobimetinib, atezolizumab, or bevacizumab formulationsXx_NEWLINE_xXHas had previous exposure to KD025 or known allergy/sensitivity to KD025 or any other ROCK-2 inhibitor.Xx_NEWLINE_xXHistory of allergy or intolerance to study drug components or polysorbate-80-containing infusionsXx_NEWLINE_xXPatients with a history of allergy to study drug components or history of a severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXHave known allergy to ovalbumin or other egg productsXx_NEWLINE_xXHave a history of allergy to iodinated contrast mediaXx_NEWLINE_xXAllergy to benzamide or inactive components of entinostat.Xx_NEWLINE_xXKnown allergy or hypersensitivity to phosphatidylinositol 3 kinase (PI3K) inhibitors or any component of the formulations used in this study.Xx_NEWLINE_xXKnown allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent; patients with a prior reaction to rituximab are permitted if the investigator feels that this reaction is manageable with standard supportive care measures and would otherwise be comfortable administering rituximab outside of the clinical trial settingXx_NEWLINE_xXKnown allergy to any of the study medications, their analogues or excipients in the various formulationsXx_NEWLINE_xXPrevious history of hypersensitivity to eggs or allergy or untoward reaction to prior vaccinia (smallpox) vaccinationXx_NEWLINE_xXKnown allergy to any of the study medications, their analogues, or excipients in the various formulations of any agentXx_NEWLINE_xXDONOR: Known allergy to filgrastim (G-CSF)Xx_NEWLINE_xXBovine product allergyXx_NEWLINE_xXKnown or suspected allergy or hypersensitivity to the study drugXx_NEWLINE_xXKnown or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trialXx_NEWLINE_xXKnown or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trialXx_NEWLINE_xXAllergy to measles vaccine or history of severe reaction to prior measles vaccinationXx_NEWLINE_xXAllergy to iodine; (NOTE: this does not include reactions to intravenous contrast materials)Xx_NEWLINE_xXPatients with a suspected allergy or sensitivity to any component of MT-3724 drug preparation based upon known allergies to compounds of a similar class who have had an anaphylactic or other severe infusion reaction to human immunoglobulin or monoclonal antibody administration are n ot eligible.Xx_NEWLINE_xXAllergy to shellfishXx_NEWLINE_xXKnown hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulationXx_NEWLINE_xXKnown allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.Xx_NEWLINE_xXMilk allergyXx_NEWLINE_xXAllergy or sensitivity to irinotecan or cranberry-grape juice, or any of the irinotecan tablet excipients. .Xx_NEWLINE_xXKnown allergy to any of the study medications, their analogues, or excipients in the various formulations of any agentXx_NEWLINE_xXKnown history of contrast allergy that cannot be medically managedXx_NEWLINE_xXEXCLUSION - TREATMENT: Known allergy to VZV vaccineXx_NEWLINE_xXKnown allergy to any of the study medications, their analogues or excipients in the various formulationsXx_NEWLINE_xXKnown allergy to HCQXx_NEWLINE_xXKnown history of allergy or intolerance which, in the opinion of the investigator, was an unacceptable adverse reaction attributed by the investigator to any prior anti-neoplastic therapy specifically targeting T-cell costimulation or immune checkpoint pathways – i.e. nivolumab (Opdivo), pembrolizumab (Keytruda), atezolizumab (Tecentriq), ipilimumab (Yervoy), etc.Xx_NEWLINE_xXHistory of grade >= 3 allergy to human monoclonal antibodiesXx_NEWLINE_xXKnown allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.Xx_NEWLINE_xXKnown allergy to eggs, egg products, aminoglycoside antibiotics (for example, gentamicin or tobramycin)Xx_NEWLINE_xXSubjects with known allergy or hypersensitivity to any component of the investigational product will be excludedXx_NEWLINE_xXPatients with known allergy or hypersensitivity to AG120 or venetoclax.Xx_NEWLINE_xXKnown allergy to both xanthine oxidase inhibitors and rasburicaseXx_NEWLINE_xXDoxycycline allergyXx_NEWLINE_xXAllergy or intolerance to roflumilastXx_NEWLINE_xXKnown or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trialXx_NEWLINE_xXKnown allergy to PEGylated productsXx_NEWLINE_xXParticipants must not have a history of allergy to nivolumab, urelumab or cabiralizumabXx_NEWLINE_xXKnown allergy or hypersensitivity to any of the study drugs or any of the study drug excipients.Xx_NEWLINE_xXThe subject has a previously identified allergy or hypersensitivity to components of the study treatment formulationXx_NEWLINE_xXHistory of allergy or hypersensitivity to study drug componentsXx_NEWLINE_xXKnown allergy or reaction to any component of either study drug formulationXx_NEWLINE_xXHistory of gastritis or malabsorption syndrome or aspirin intolerance or allergyXx_NEWLINE_xXHistory of allergy to study drug components.Xx_NEWLINE_xXHas a contraindication (sensitivity or allergy) to trimethoprim/sulfamethoxazole and ampicillin.Xx_NEWLINE_xXPatients with a known allergy or delayed hypersensitivity reaction to drugs chemically related to X-396 (e.g., crizotinib) or to the active ingredient of X-396.Xx_NEWLINE_xXKnown hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or to any component of the atezolizumab formulationXx_NEWLINE_xXA previously identified allergy or hypersensitivity to components of the study treatment formulation.Xx_NEWLINE_xXAny history of allergy to the study drug componentsXx_NEWLINE_xXKnown allergy to the study drugs or any of its componentsXx_NEWLINE_xXBupivacaine or liposomal bupivacaine sensitive or known allergy.Xx_NEWLINE_xXKnown allergy or hypersensitivity to any of the study drugs or any of their excipientsXx_NEWLINE_xXAny history of allergy to the study drug componentsXx_NEWLINE_xXSubjects with an allergy to contrast agents may be enrolled at the treating physician’s discretion with appropriate pre-treatment and symptom managementXx_NEWLINE_xXA known allergy, intolerance, or medical contraindication to receiving the contrast dye required for the protocol-specified CT imagingXx_NEWLINE_xXKnown allergy or reaction to any component of either study drug formulationXx_NEWLINE_xXKnown allergy to eggs, egg products, aminoglycoside antibiotics (e.g. gentamicin or tobramycin)Xx_NEWLINE_xXKnown allergy to anthracyclines.Xx_NEWLINE_xXPreviously identified allergy or hypersensitivity to any component of the study treatment formulationsXx_NEWLINE_xXAllergy to any component of MSC suspension (such as human albumin) and/or allergy to any drugs used in HCT conditioning regimenXx_NEWLINE_xXKnown or suspected allergy to the investigational agent or any agent given in association with this trialXx_NEWLINE_xXHistory of allergy to merestinib or chemically related compoundsXx_NEWLINE_xXAn allergy or intolerance to egg, gluten or milk proteinXx_NEWLINE_xXKnown allergy to any of the study medications, their analogues, or excipients in the various formulations of any agentXx_NEWLINE_xXAn allergy to a component of LevulanXx_NEWLINE_xXSevere hypersensitivity reaction to treatment during prior administration of a monoclonal antibody (mAb) or history of allergy to any study drug componentXx_NEWLINE_xXHistory of allergy or intolerance (unacceptable adverse event) to study drugs components.Xx_NEWLINE_xXSubject has known history of allergy, hypersensitivity, or any serious reaction to any of the azole class antifungals.Xx_NEWLINE_xXHas an allergy or hypersensitivity to chili peppers, capsaicin, or radiographic contrast agents.Xx_NEWLINE_xXKnown history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)Xx_NEWLINE_xXPatient has a history of allergy to red color food dye or any other component of Qapzola, placebo, or their diluentsXx_NEWLINE_xXKnown allergy to both xanthine oxidase inhibitors and rasburicase; or, known hypersensitivity to any of the study drugsXx_NEWLINE_xXPreviously identified allergy or hypersensitivity to components of the study treatment formulationsXx_NEWLINE_xXAllergy to benzamide or inactive components of entinostatXx_NEWLINE_xXKnown hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulationXx_NEWLINE_xXKnown allergy or intolerance to any component of belimumab, including human or murine proteins or monoclonal antibodiesXx_NEWLINE_xXKnown allergy or hypersensitivity to IPXx_NEWLINE_xXAllergy or hypersensitivity to components of the cobimetinib formulationXx_NEWLINE_xXKnown allergy to any of the study medications, their analogues or excipients in the various formulationsXx_NEWLINE_xXhave a known or suspected allergy to the study drug or any study drug component;Xx_NEWLINE_xXAllergy to carfilzomib or cabozantinib or any excipientsXx_NEWLINE_xXKnown allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficultyXx_NEWLINE_xXHas known allergy or reaction to any component of either study drug or formulation componentsXx_NEWLINE_xXHistory of allergy to mouse proteinsXx_NEWLINE_xXHistory of allergy to study drug componentsXx_NEWLINE_xXHistory of sensitivity or allergy to monoclonal antibodies (mAbs) or immunoglobulin G (IgG)Xx_NEWLINE_xXKnown allergy to murine proteins or have had a documented anaphylactic reaction to any drug, or a known hypersensitivity to diphenhydramine or other antihistamines of similar chemical structure.Xx_NEWLINE_xXKnown hypersensitivity or allergy to any component of the avelumab formulationXx_NEWLINE_xXHas a previously identified allergy or hypersensitivity to components of the study treatment formulationsXx_NEWLINE_xXKnown allergy or hypersensitivity to intraperitoneal (IP) or any excipientXx_NEWLINE_xXKnown hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab or bevacizumab formulationXx_NEWLINE_xXAllergy to murine-based monoclonal antibodiesXx_NEWLINE_xXKnown allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficultyXx_NEWLINE_xXPatients with allergies or adverse drug reactions to the following are not eligible:\r\n* History of allergy to study drug components;\r\n* History of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXAllergies and adverse drug reaction; a) history of allergy to study drug components; b) history of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXHistory of allergy to study drug componentsXx_NEWLINE_xXKnown or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trialXx_NEWLINE_xXKnown allergy to grapes or grape seedXx_NEWLINE_xXAllergy to pembrolizumab or related compoundsXx_NEWLINE_xXKnown allergy to nab-paclitaxel or gemcitabine or any ingredient of study drug formulations.Xx_NEWLINE_xXPatients with unconfirmed allergies to piperacillin-tazobactam, cefepime, aztreonam or vancomycin can be evaluated by an allergy/immunology specialist, after which they may become eligible by a consensus of the treating physician, trial investigator and the allergy/immunology specialistXx_NEWLINE_xXA known allergy or history of hypersensitivity to silicon, phosphorous or any of the OncoSil™ componentsXx_NEWLINE_xXPatients with a known allergy to Zometa or to antiemetics appropriate for administration in conjunction with protocol-directed therapyXx_NEWLINE_xXHistory of grade 3 or higher allergy to humanized monoclonal antibodiesXx_NEWLINE_xXKnown allergy or intolerance to lidocaineXx_NEWLINE_xXPatients with a known hypersensitivity/allergy to any of the standard of care agents used in this study or related compounds (e.g. platinum compounds) are excludedXx_NEWLINE_xXPatients with albumin allergyXx_NEWLINE_xXGadolinium allergyXx_NEWLINE_xXKnown or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trialXx_NEWLINE_xXPatients with an allergy, or have experienced any drug reaction to ketamine will be excludedXx_NEWLINE_xXHistory of allergy to study drug componentsXx_NEWLINE_xXAllergy to benzamide or inactive components of entinostatXx_NEWLINE_xXKnown allergy to coenzyme Q10Xx_NEWLINE_xXKnown allergy or adverse reaction to oral, subcutaneous, or intravenous vitamin KXx_NEWLINE_xXHistory of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine productsXx_NEWLINE_xXKnown allergy or hypersensitivity to any component of the investigational drug product.Xx_NEWLINE_xXKnown allergy to doxycycline or tetracyclineXx_NEWLINE_xXHistory of allergy or adverse drug reaction to study componentsXx_NEWLINE_xXKnown adverse reactions to heparin (heparin-induced thrombocytopenia or any allergy)Xx_NEWLINE_xXKnown allergy or hypersensitivity to investigational product (IP) or any excipientXx_NEWLINE_xXKnown allergy to ODM-201 or any of the excipients.Xx_NEWLINE_xXKnown allergy to both xanthine oxidase inhibitors and rasburicaseXx_NEWLINE_xXKnown or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trialXx_NEWLINE_xXPatients with severe, active co-morbidity, defined as follow:\r\n* Patients with an active infection requiring intravenous treatment or having an unexplained febrile illness (maximum temperature [Tmax] > 99.5 degrees Fahrenheit [F]/37.5 degrees Celsius [C])\r\n* Patients with known immunosuppressive disease or known human immunodeficiency virus infection\r\n* Patients with unstable or severe intercurrent medical conditions such as severe heart disease (New York Heart Association class 3 or 4)\r\n* Patients with known lung (forced expiratory volume in 1 second [FEV1] < 50%) disease or uncontrolled diabetes mellitus\r\n* Patients with albumin allergy\r\n* Patients with gadolinium allergyXx_NEWLINE_xXHistory of allergy to study drug componentsXx_NEWLINE_xXHistory of allergy to components of nivolumab or DS-8273A, or known allergy to other antibody therapiesXx_NEWLINE_xXKnown or suspected allergy to lenvatinib or any agent given in the course of this trialXx_NEWLINE_xXKnown allergy to any of the study medications, their analogs, or excipients in the various formulations of any agentXx_NEWLINE_xXHistory of allergy or adverse drug reaction to the study drug components (nivolumab, dabrafenib, or trametinib) or drugs of similar chemical or biologic composition; patients with a history of severe hypersensitivity reaction to any monoclonal antibody should also be excludedXx_NEWLINE_xXAny known allergy or allergic reactions to CaptisolXx_NEWLINE_xXKnown allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent; specifically, prior desquamating rash or erythema nodosum during prior thalidomide or other similar agentsXx_NEWLINE_xXKnown allergy or hypersensitivity to Keyhole Limpet Hemocyanin (KLH), sargramostim (GM-CSF) or yeast derived products, or a history of anaphylactic reactions to shellfish proteinsXx_NEWLINE_xXHistory of severe allergy (e.g., anaphylaxis) to any component of Prevnar or any diphtheria?toxoid containing vaccineXx_NEWLINE_xXPatients must not have a history of severe allergic reactions (i.e., grade 4 allergy, anaphylactic reaction from which the subject did not recover within 6 hours of institution of supportive care) to any unknown allergens or any components of the nivolumab formulationsXx_NEWLINE_xXKnown allergy or hypersensitivity to study drug formulationsXx_NEWLINE_xXHistory of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or Medical Monitor, contraindicates their participation.Xx_NEWLINE_xXHistory of allergy or hypersensitivity to albumin-bound paclitaxel, or gemcitabineXx_NEWLINE_xXPatients with known allergy to cremophor or polysorbate 80Xx_NEWLINE_xXKnown allergy or hypersensitivity to any of the study drugs or any of the study drug excipientsXx_NEWLINE_xXKnown allergy to PIOXx_NEWLINE_xXPatients may not have any known allergy to CYP and/or GM-CSF.Xx_NEWLINE_xXAllergy to measles vaccine or history of severe reaction to prior measles vaccinationXx_NEWLINE_xXAllergy to iodine; Note: this does not include reactions to intravenous contrast materialsXx_NEWLINE_xXKnown allergy to any of the study medications, their analogues or excipients in the various formulationsXx_NEWLINE_xXAllergies and adverse drug reaction to the following: history of allergy to study drug components; history of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXAllergy to X ray contrast agents.Xx_NEWLINE_xXSevere allergy to contrast agent.Xx_NEWLINE_xXAllergy or hypersensitivity to agents used within the treatment protocolXx_NEWLINE_xXHistory of allergy to mouse proteinsXx_NEWLINE_xXKnown allergy to eggs, egg products, aminoglycoside antibiotics (for example, gentamicin or tobramycin)Xx_NEWLINE_xXPatients who have known allergy to mebendazoleXx_NEWLINE_xXDONOR: Known allergy or hypersensitivity to any of the test compounds, materials, or contraindication to test productsXx_NEWLINE_xXHistory of sensitivity or allergy to monoclonal antibodies or immunoglobulin GXx_NEWLINE_xXKnown history of allergy or hypersensitivity to study product excipients (human serum albumin, dimethyl sulfoxide [DMSO], and dextran 40)Xx_NEWLINE_xXKnown allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent; patient cannot be allergic to boronXx_NEWLINE_xXAllergy or hypersensitivity to components of the vemurafenib formulationXx_NEWLINE_xXHistory of allergy to study drug componentsXx_NEWLINE_xXCERITINIB EXCLUSION CRITERIA: Previously identified allergy or hypersensitivity to components of ceritinib formulationXx_NEWLINE_xXREGORAFENIB EXCLUSION CRITERIA: Previously identified allergy or hypersensitivity to components of regorafenib formulationXx_NEWLINE_xXENTRECTINIB EXCLUSION CRITERIA: Previously identified allergy or hypersensitivity to components of entrectinib formulationXx_NEWLINE_xXKnown allergy to any of the study medications, their analogues, or excipients in the various formulations of any agentXx_NEWLINE_xXNo contraindication to receiving radiotherapy and no known allergy to components of fresolimumabXx_NEWLINE_xXPatient has a history of allergy or intolerance to flucytosine.Xx_NEWLINE_xXPatients with known allergy or hypersensitivity to selinexor, sorafenib or any of its componentsXx_NEWLINE_xXPatients with known allergy to bovine or murine productsXx_NEWLINE_xXKnown allergy or hypersensitivity to tetanus, or any other tetanus or diphtheria toxoid-containing vaccine, or any component of this vaccine (i.e., aluminum phosphate, formaldehyde)Xx_NEWLINE_xXKnown severe (grade 3 or 4) infusion-related allergy or hypersensitivity to any monoclonal antibodyXx_NEWLINE_xXKnown allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib).Xx_NEWLINE_xXKnown or suspected allergy or hypersensitivity to regorafenib, or excipients of the formulations given during the course of this trialXx_NEWLINE_xXPreviously identified allergy or hypersensitivity to components of the study treatment formulationsXx_NEWLINE_xXHave known severe intolerance to or life-threatening hypersensitivity reactions to humanized monoclonal antibodies or intravenous immunoglobulin preparations; any history of anaphylaxis; prior history of human anti-human antibody response; known allergy to any of the study medications, their analogues, or excipients in the various formulations of any agentXx_NEWLINE_xXKnown allergy to any of the study medications, their analogues, or excipients in the various formulations of any agentXx_NEWLINE_xXPatients with known carboplatin or cisplatin allergyXx_NEWLINE_xXHistory of allergy to study treatments or any of its components of the study arm that participant is enrollingXx_NEWLINE_xXAllergies and adverse drug reaction\r\n* History of allergy to study drug components\r\n* History of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXNo life-threatening allergy to baker’s yeast or other components of the vaccines; no history of allergic reactions to the antibiotics neomycin, streptomycin or polymyxin BXx_NEWLINE_xXHistory of allergy to study drug componentsXx_NEWLINE_xXKnown allergy or hypersensitivity to any of the test compounds, materials or contraindication to test product.Xx_NEWLINE_xXKnown allergy to sulfa or specific allergy to sulfonylurea drugsXx_NEWLINE_xXAllergy to gadoliniumXx_NEWLINE_xXKnown allergy, hypersensitivity or prior infusion reaction to one or more of the therapies incorporated into this treatment protocolXx_NEWLINE_xXPatients with a known allergy to cisplatin chemotherapy; patients with carboplatin allergy may be included if they tolerate a test dose of intravenous (IV) cisplatin given in monitored floor conditionsXx_NEWLINE_xXKnown allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficultyXx_NEWLINE_xXKnown allergy to any of the study medications, their analogues, or excipients in the various formulationsXx_NEWLINE_xXKnown allergy to any of the study medications, their analogues, or excipients in the various formulations of any agentXx_NEWLINE_xXKnown hypersensitivity or allergy to Chinese hamster ovary cell products or any component of the MDPL3280A formulationXx_NEWLINE_xXPatients with known allergy or hypersensitivity to nivolumab, ipilimumab, 5-azacytidine, or any of their componentsXx_NEWLINE_xXAllergy to filgrastim, pegfilgrastim, or loratadineXx_NEWLINE_xXHistory of allergy to mannitolXx_NEWLINE_xXKnown allergy to any of the study medications, their analogues, or excipients in the various formulations of any agentXx_NEWLINE_xXKnown allergy to any of the study medications, their analogues, or excipients in the various formulations of any agentXx_NEWLINE_xXPatients must not have a known history of yeast allergy; if patient has a questionable history of allergy to yeast, a yeast skin test can be performed; patients would be eligible if skin test is negative (note, patients may not be on tricyclic antidepressants at the time of yeast skin test)Xx_NEWLINE_xXHistory of allergy or untoward reaction to yeast-based products (any hypersensitivity to yeast-based products will be excluded)Xx_NEWLINE_xXPatient does not have known allergy to polyethylene glycol hydrogel (spacer material)Xx_NEWLINE_xXHistory of allergy to study drug components or history of severe hypersensitivity reaction of any monoclonal antibodyXx_NEWLINE_xXKnown allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficultyXx_NEWLINE_xXKnown allergy to ixazomib, its analogues, or excipients in the various formulations of ixazomibXx_NEWLINE_xXGold allergyXx_NEWLINE_xXHistory of allergy or hypersensitivity to nivolumab componentsXx_NEWLINE_xXPatients with a known allergy to gadolinium-DTPAXx_NEWLINE_xXA previously identified allergy or hypersensitivity to components of the study treatment formulationXx_NEWLINE_xXKnown history of allergy to Captisol®Xx_NEWLINE_xXKnown or suspected allergy or hypersensitivity to sorafenibXx_NEWLINE_xXHistory of allergy to study drug componentsXx_NEWLINE_xXKnown allergy or reaction to any component of the MEDI4736 formulation or its excipientsXx_NEWLINE_xXPatients with known allergy, intolerance, or resistance (i.e., remission duration less than 6 months or lack of response) to ifosfamide, carboplatin, or etoposideXx_NEWLINE_xXKnown allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficultyXx_NEWLINE_xXPatients with a known allergy to dimethyl sulfoxide (DMSO)Xx_NEWLINE_xXAllergy or hypersensitivity to tetanus vaccine or any component of the tetanus vaccineXx_NEWLINE_xXKnown allergy to fluoropyrimidines or known dihydropyrimidine dehydrogenase (DPD) deficiency.Xx_NEWLINE_xXPatients with a known history of allergy to soy productsXx_NEWLINE_xXPatients with a known history of a severe allergy or sensitivity to wheat glutenXx_NEWLINE_xXMAIN STUDY COHORT EXCLUSION CRITERIA: History of other malignancy with concern for renal metastasis and known allergy to technetium or sestamibiXx_NEWLINE_xXRENAL CELL CARCINOMA (RCC) COHORT EXCLUSION CRITERIA: History of other malignancy with concern for renal metastasis and known allergy to technetium or sestamibiXx_NEWLINE_xXPrevious severe or life-threatening allergic reaction with rituximab or known allergy to the compounds found in INCB7839Xx_NEWLINE_xXThe subject has a previously identified allergy or hypersensitivity to components of the study treatment formulationXx_NEWLINE_xXSubjects with known allergy to lidocaine, epinephrine, itraconazole or petrolatumXx_NEWLINE_xXHistory of allergy to mouse proteinsXx_NEWLINE_xXAllergy to measles vaccine or history of severe reaction to prior measles vaccinationXx_NEWLINE_xXAllergy to iodine; this does not include reactions to intravenous contrast materialsXx_NEWLINE_xXThe subject has a previously identified allergy or hypersensitivity to components of the study treatment formulationXx_NEWLINE_xXPatients with NSAIDs allergies, known lactose allergy, a history of recent gastrointestinal (GI) bleed (less than 2 weeks), and those who are on therapeutic dose anticoagulants will be excluded from this protocolXx_NEWLINE_xXKnown history of allergy to Captisol (a cyclodextrin derivative used to solubilize CFZ), or similar chemical or biologic composition to bendamustine or other agents used in the studyXx_NEWLINE_xXThe patient has a contraindication (e.g. sensitivity/allergy) to both trimethoprim/sulfamethoxazole and ampicillinXx_NEWLINE_xXPatients with a known allergy to any component of the study treatment formulationsXx_NEWLINE_xXKnown history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)Xx_NEWLINE_xXMust not have any known history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib).Xx_NEWLINE_xXHistory of allergy to penicillin or related antibioticXx_NEWLINE_xXPatients with known allergy or hypersensitivity to quizartinib, mannitol, AZA, cytarabine or any of their components.Xx_NEWLINE_xXPreviously identified allergy or hypersensitivity or intolerance to components of the study treatment formulation (cyclophosphamide, capecitabine, lapatinib [lapatinib ditosylate], trastuzumab)Xx_NEWLINE_xXPatients with an allergy or known hypersensitivity to fishXx_NEWLINE_xXKnown allergy to any of the agents or their ingredients used in this studyXx_NEWLINE_xXKnown allergy to sargramostim (GM-CSF)Xx_NEWLINE_xXPatients who are known to have allergy to mouse proteinsXx_NEWLINE_xXAllergy to valacyclovir or unable to take oral tabletsXx_NEWLINE_xXHistory of allergy to mouse proteinsXx_NEWLINE_xXHistory of allergy to GM-CSFXx_NEWLINE_xXAllergy to oseltamivir or excipientsXx_NEWLINE_xXKnown allergy to domperidoneXx_NEWLINE_xXKnown severe or life-threatening allergy or intolerance to fludarabine, alemtuzumab, cyclosporine, or mycophenolate mofetil.Xx_NEWLINE_xXCOHORTS 1 AND 2: HEALTHY VOLUNTEERS: Known allergy or sensitivity to sodium hypochlorite (NaOCl)Xx_NEWLINE_xXKnown or suspected allergy to sorafenib, everolimus, or any agent given in the course of this trialXx_NEWLINE_xXPatients with latex allergy.Xx_NEWLINE_xXKnown allergy to any of the study medications, their analogues or excipients in the various formulationsXx_NEWLINE_xXKnown allergy to any of the treatment componentsXx_NEWLINE_xXHistory of allergy to mouse proteinsXx_NEWLINE_xXPatients who have an allergy to gold.Xx_NEWLINE_xXCorn allergyXx_NEWLINE_xXHistory of allergy to KLH, QS-21, OPT-821, or glucanXx_NEWLINE_xXKnown allergy to any of the study medications, their analogues, or excipients in the various formulations of any agentXx_NEWLINE_xXHistory of allergy or hypersensitivity to any systemically administered antibody agent or its excipientsXx_NEWLINE_xXKnown allergy/hypersensitivity to drug or componentsXx_NEWLINE_xXKnown hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or to any component of the atezolizumab formulationXx_NEWLINE_xXPatients may not have any known allergy to CYP and/or GM-CSF.Xx_NEWLINE_xXHistory of photosensitizing disease (porphyria, lupus etc.) or of allergy to methylene blue dye.Xx_NEWLINE_xXKnown history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)Xx_NEWLINE_xXPatients who have a known history of allergy to Captisol (a cyclodextrin derivative used to stabilize carfilzomib) are NOT eligible for participationXx_NEWLINE_xXPatients are excluded if there is any history of gadolinium allergy.Xx_NEWLINE_xXPatient having known allergy to NSAID or AspirinXx_NEWLINE_xXKnown allergy to doxorubicin or anthracyclines.Xx_NEWLINE_xXHistory of allergy or hypersensitivity to the device constituent or Inserter materials.Xx_NEWLINE_xXHistory of allergy or hypersensitivity to nivolumab drug components.Xx_NEWLINE_xXKnown allergy or hypersensitivity to the components of the atezolizumab formulation or to any of the study drugs or excipients, (e.g., Cremophor EL)Xx_NEWLINE_xXSubjects with hypersensitivity or allergy to tetracycline antibiotics or edetate disodium;Xx_NEWLINE_xXHistory of allergy or hypersensitivity to any of the study drugs.Xx_NEWLINE_xXORAL CAVITY SQUAMOUS CELL CARCINOMA COHORT: Allergy to ciprofloxacin (or other quinolones), acetylsalicylic acidXx_NEWLINE_xXKnown allergy or hypersensitivity to any of the study drugsXx_NEWLINE_xXPatients with known allergy to bovine or murine products.Xx_NEWLINE_xXPart 2: have a major contraindication to MP (e.g., allergy/hypersensitivity to study medications or their constituents), or conditions making adherence difficult as determined by the attending physicianXx_NEWLINE_xXKnown allergy to any of the study medications, their analogues, or excipients in the various formulations of any agentXx_NEWLINE_xXKnown allergy or hypersensitivity to any of the study drugs or any of the study drug excipientsXx_NEWLINE_xXPatient has a prior allergy or intolerance of ketoconazoleXx_NEWLINE_xXPatient has an allergy or intolerance to sulfitesXx_NEWLINE_xXPatients with known allergy to MBXx_NEWLINE_xXPreviously identified allergy or hypersensitivity to components of the study treatment formulationsXx_NEWLINE_xXKnown allergy(ies) to any component of CMB305 or LV305.Xx_NEWLINE_xXKnown allergy or hypersensitivity to study treatment or any of the study drugs excipients.Xx_NEWLINE_xXKnown allergy, or history of serious adverse reaction to, vaccines such as anaphylaxis, hives, or respiratory difficulty.Xx_NEWLINE_xXKnown or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trialXx_NEWLINE_xXHistory of ? grade 3 allergic reactions to monoclonal antibody therapy as well as known or suspected allergy or intolerance to any agent given in the course of this trial.Xx_NEWLINE_xXAllergy to measles vaccine or history of severe reaction to prior measles vaccinationXx_NEWLINE_xXKnown allergy to hyaluronidaseXx_NEWLINE_xXHistory of allergy or hypersensitivity to any of the study drugs or study drug componentsXx_NEWLINE_xXAllergy to measles vaccine or history of severe reaction to prior measles vaccinationXx_NEWLINE_xXAllergy to iodine\r\n* Note: This does not include reactions to intravenous contrast materialsXx_NEWLINE_xXAllergy to measles vaccine or history of severe reaction to prior measles vaccinationXx_NEWLINE_xXDose Escalation cohort only: Allergy to iodine; NOTE: this does not include reactions to intravenous contrast materialsXx_NEWLINE_xXDOSE ESCALATION COHORT: Known allergy or reaction to any component of either study drug formulation; any history of serotonin syndrome (SS) after receiving 1 or more serotonergic drugsXx_NEWLINE_xXDOSE EXPANSION COHORT: Known allergy or reaction to any component of either study drug formulation; any history of serotonin syndrome (SS) after receiving 1 or more serotonergic drugsXx_NEWLINE_xXAny history of allergy to the study drug componentsXx_NEWLINE_xXHistory of allergy to study drug components.Xx_NEWLINE_xXPatients with prior allergy to daunorubicin and/or cytarabineXx_NEWLINE_xXPatients with known allergy to intravenous iodinated contrast agentsXx_NEWLINE_xXPatients who have an allergy/intolerance to sirolimusXx_NEWLINE_xXThe subject has a previously-identified allergy or hypersensitivity to components of the study treatment formulationXx_NEWLINE_xXDONOR: Known allergy to filgrastim (GCSF)Xx_NEWLINE_xXAllergy to measles vaccine or history of severe reaction to prior measles vaccinationXx_NEWLINE_xXKnown history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)Xx_NEWLINE_xXHistory of allergy or hypersensitivity to any component of the treatmentXx_NEWLINE_xXHistory of severe environmental allergies or allergy to egg proteinsXx_NEWLINE_xXAllergy/sensitivity to any study drug (gemcitabine, cisplatin, enzalutamide), or drugs chemically related to study drug, or excipientsXx_NEWLINE_xXAllergy to or intolerance of prior doxorubicin-based TACEXx_NEWLINE_xXAllergy to or intolerance to iodinated contrast media despite standard of care pre-medicationXx_NEWLINE_xXKnown or suspected allergy or hypersensitivity to any of the study drug classesXx_NEWLINE_xXHistory of allergy to egg proteinsXx_NEWLINE_xXKnown history of allergy to Captisol®Xx_NEWLINE_xXSoy allergyXx_NEWLINE_xXKnown allergy to any of the study medications, their analogues, or excipients in the various formulations of any agentXx_NEWLINE_xXKnown allergy to any of the study medications, their analogues, or excipients in the various formulations of any agentXx_NEWLINE_xXHistory of allergy or untoward reaction to prior vaccination with vaccinia virusXx_NEWLINE_xXPrevious monoclonal antibody (mAb) or other treatment specifically directed against CD19; history of serious allergy or reaction to any component of the MEDI-551 formulation that would prevent administrationXx_NEWLINE_xXKnown allergy or hypersensitivity to azacitidine, mannitol, or midostaurinXx_NEWLINE_xXKnown or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trialXx_NEWLINE_xXPatients must not have any known allergy or reaction to any component of the nivolumab and ipilimumab formulationsXx_NEWLINE_xXAllergies and Adverse Drug Reaction a) History of allergy to study drug components b) History of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXLocal or severe allergy to any components of the drug regimen.Xx_NEWLINE_xXPatient must not have a known allergy to any of the treatment componentsXx_NEWLINE_xXKnown allergy or hypersensitivity to components of the FPA144 formulation including polysorbateXx_NEWLINE_xXKnown allergy(ies) to any component of CMB305, atezolizumab, or severe allergic reactions to monoclonal antibodies, fusion proteins, or CHO cell products.Xx_NEWLINE_xXKnown history of positive serum human ADA, or known allergy to any component of ADCT-301.Xx_NEWLINE_xXKnown allergy(ies) to any component of CMB305 or CPAXx_NEWLINE_xXSubject has a history of allergy or hypersensitivity to any study drugs or their excipients.Xx_NEWLINE_xXFor the Combination Dose Finding and Combination Expansion cohorts only: previously identified allergy or hypersensitivity to components of the study treatment formulation or panitumumabXx_NEWLINE_xXPatients with known floxuridine, leucovorin (leucovorin calcium), or mitomycin (mitomycin C) allergyXx_NEWLINE_xXKnown allergy to boron, MLN9708, any of the study treatments, their analogues, or excipients.Xx_NEWLINE_xXHistory of severe peripheral allergy or intolerance to contrast agents, narcotics, sedatives or atropine that cannot be managed medicallyXx_NEWLINE_xXAllergy or contraindications to administration of the GI anti-spasmodic drug:Xx_NEWLINE_xXPatients must not have any known allergy or reaction to any component of the MEDI4736 formulationXx_NEWLINE_xXSubject has a history of allergy or hypersensitivity to study drug components;Xx_NEWLINE_xXKnown allergy to both penicillin and sulfa antibioticsXx_NEWLINE_xXKnown allergy to xanthine oxidase inhibitors and/or rasburicase for subjects at risk for TLSXx_NEWLINE_xXPrior demonstrated hypersensitivity, intolerance or allergy to abiraterone acetate, prednisone or their excipientsXx_NEWLINE_xXNo known allergy to platinum compoundsXx_NEWLINE_xXHistory of severe hypersensitivity reaction to any monoclonal antibody or allergy to study drug componentsXx_NEWLINE_xXHistory of allergy to mesothelin-directed antibodies, tubulysin, monoclonal antibodies, nivolumab or related compoundsXx_NEWLINE_xXHistory of allergy or hypersensitivity to human, humanized or chimeric monoclonal antibodiesXx_NEWLINE_xXKnown or suspected allergy to any agent given in the course of this trialXx_NEWLINE_xXHistory of severe allergy or intolerance to contrast agents, narcotics sedatives or atropine that cannot be managed medicallyXx_NEWLINE_xXKnown allergy to latex or gadolinium (Gd).Xx_NEWLINE_xXKnown allergy or hypersensitivity to any component of the atezolizumab formulationXx_NEWLINE_xXKnown allergy or hypersensitivity to any component of the bevacizumab formulationXx_NEWLINE_xXAllergies and adverse drug reaction\r\n* History of allergy to study drug components\r\n* History of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXhave a known allergy or hypersensitivity reaction to any of the treatment componentsXx_NEWLINE_xXHave a known allergy or hypersensitivity reaction to any of the treatment components.Xx_NEWLINE_xXKnown allergy or past administration reaction including infusion related reaction (IRRs), anaphylactic, or anaphylactoid reactions to any component of the CDX-0158 formulation.Xx_NEWLINE_xXAllergy to ciprofloxacin (or other quinolones), acetylsalicylic acid, or indomethacin.Xx_NEWLINE_xXKnown allergy, or history of serious adverse reaction to, vaccines such as anaphylaxis, hives, or respiratory difficultyXx_NEWLINE_xXKnown hypersensitivity or allergy sunitinib or to chemically related products or likely to be exacerbated to by any component of the study productsXx_NEWLINE_xXKnown or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial.Xx_NEWLINE_xXPatients with known allergy or hypersensitivity to lirilumab, 5-azacytidine, or any of their components; patients who have previously been treated with lirilumab in combination with 5-azacytidine will be excludedXx_NEWLINE_xXHave a known allergy / history of hypersensitivity reaction to any of the treatment components, including any ingredient used in the formulation of necitumumab, or any other contraindication to one of the administered treatments.Xx_NEWLINE_xXKnown allergy to iron dextran or presence of human anti-mouse antibodiesXx_NEWLINE_xXHave known allergy or hypersensitivity to any components of study treatment.Xx_NEWLINE_xXHistory of allergy to murine proteinsXx_NEWLINE_xXHistory of allergy or hypersensitivity to study product excipients (human serum albumin, dimethyl sulfoxide [DMSO], and Dextran 40)Xx_NEWLINE_xXA history of allergy to human monoclonal antibodies.Xx_NEWLINE_xXPatients with known allergy to sorafenib or azacitidine, mannitol or any of their componentsXx_NEWLINE_xXKnown or suspected allergy to sorafenib or any agent given in the course of this trialXx_NEWLINE_xXKnown allergy(ies) to any component of the study agent GLA-SE including egg lecithinXx_NEWLINE_xXHistory of allergy to murine proteinsXx_NEWLINE_xXHistory of allergy or hypersensitivity to study product excipients (human serum albumin, dimethyl sulfoxide [DMSO], and Dextran 40)Xx_NEWLINE_xXHave a known allergy to tomatoes or have never consumed tomatoesXx_NEWLINE_xXHistory of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine productsXx_NEWLINE_xXKnown allergy to any of the study medications, their analogues, or excipients in the various formulations of any agentXx_NEWLINE_xXHistory of allergy to components of ipilimumab or panobinostat, or known allergy to other antibody therapiesXx_NEWLINE_xXKnown sensitivity or allergy to murine products.Xx_NEWLINE_xXKnown allergy to thalidomide.Xx_NEWLINE_xXPatients must not have a known allergy to mannitolXx_NEWLINE_xXKnown allergy to ovalbumin or other egg productsXx_NEWLINE_xXThe subject has a previously identified allergy or hypersensitivity to components of the study treatment formulationXx_NEWLINE_xXSubject has a known allergy to ART-123 or any components of the drug product.Xx_NEWLINE_xXAllergy to ganciclovir or acyclovirXx_NEWLINE_xXHistory of allergy to mouse proteinsXx_NEWLINE_xXSubjects with known allergy or hypersensitivity to any component of the investigational product will be excludedXx_NEWLINE_xXKnown allergy to both xanthine oxidase inhibitors and rasburicaseXx_NEWLINE_xXAllergies and Adverse Drug Reaction: History of allergy to study drug componentsXx_NEWLINE_xXHistory of allergy to study drug componentsXx_NEWLINE_xXHas known or suspected allergy or sensitivity to any test materials, reagents, or WCE contrast materialsXx_NEWLINE_xXSubject has a known sensitivity or allergy to bovine and/or porcine substance(s) or any other component(s) of the hemostatic agent;Xx_NEWLINE_xXKnown allergy to any of the study medications, their analogues, or excipients in the various formulations of any agentXx_NEWLINE_xXKnown allergy to eggs, egg products, aminoglycoside antibiotics (for example, gentamicin or tobramycin)Xx_NEWLINE_xXKnown allergy to both penicillin and trimethoprim/sulfamethoxazole. Participants who are allergic to only one of these antibiotics are allowed to enrollXx_NEWLINE_xXKnown allergy or hypersensitivity to IP formulations or to other human monoclonal antibodiesXx_NEWLINE_xXPatient has a history of allergy to red color food dye.Xx_NEWLINE_xXContraindication to use of gadolinium-based intravenous contrast, including life-threatening allergy or compromised renal function (creatinine > 2.0)Xx_NEWLINE_xXA known allergy to any component of LY2157299.Xx_NEWLINE_xXKnown allergy to any of the study medications, their analogues, or excipients in the various formulations of any agentXx_NEWLINE_xXHistory of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)Xx_NEWLINE_xXKnown allergy to hyaluronidaseXx_NEWLINE_xXThe participant has a known allergy / history of hypersensitivity reaction to any of the treatment components, including any ingredient used in the formulation of necitumumab or pembrolizumab, or any other contraindication to one of the administered treatments.Xx_NEWLINE_xXAllergy to meclofenamate or other nonsteroidal antiinflammatory drug (NSAID)Xx_NEWLINE_xXHistory of allergy or intolerance (unacceptable adverse event) to study drugs componentsXx_NEWLINE_xXKnown history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)Xx_NEWLINE_xXPreviously identified allergy or hypersensitivity to components of the study treatment formulationsXx_NEWLINE_xXKnown allergy to any of the study medications, their analogues, or excipients in the various formulations of any agentXx_NEWLINE_xXKnown or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trialXx_NEWLINE_xXKnown allergy or hypersensitivity to paclitaxel or any components used in the paclitaxel preparation or other contraindication for taxane therapyXx_NEWLINE_xXSubjects with a known allergy to polyethylene glycol hydrogel (spacer material) or contraindication to spacer products (Duraseal or SpaceOAR)Xx_NEWLINE_xXKnown allergy to pembrolizumab or any of its excipients.Xx_NEWLINE_xXKnown allergy to any of the vaccine or adjuvant components, including eggsXx_NEWLINE_xXKnown allergy or hypersensitivity to Investigational Product.Xx_NEWLINE_xXPatients with documented allergy to cephalosporinsXx_NEWLINE_xXPatients may not have a known allergy or hypersensitivity to any of the components of the investigational therapy, including polyethylene glycol (PEG) or topoisomerase inhibitorsXx_NEWLINE_xXHas allergy to enzalutamideXx_NEWLINE_xXKnown history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)Xx_NEWLINE_xXPatient has a known allergy to both penicillin and sulfaXx_NEWLINE_xXHistory of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine productsXx_NEWLINE_xXKnown allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.Xx_NEWLINE_xXKnown or suspected allergy to the investigational agent or any agent given in association with this trialXx_NEWLINE_xXAll patients who have received prior vaccination with vaccinia virus (for smallpox immunization) must not have a history of allergy to the vaccineXx_NEWLINE_xXPatients with known allergy to eggsXx_NEWLINE_xXSubject has known contraindication or allergy to both xanthine oxidase inhibitors and rasburicase.Xx_NEWLINE_xXKnown allergy to any of the study medications, their analogues, or excipients in the various formulations of any agentXx_NEWLINE_xXKnown or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trialXx_NEWLINE_xXKnown or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trialXx_NEWLINE_xXKnown history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)Xx_NEWLINE_xXKnown or suspected allergy to sorafenib or any agent given in the course of this trialXx_NEWLINE_xXKnown history of allergy to CaptisolXx_NEWLINE_xXNo known history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)Xx_NEWLINE_xXAllergy to soy, egg, or peanut productsXx_NEWLINE_xXKnown allergy to both xanthine oxidase inhibitors and rasburicaseXx_NEWLINE_xXAllergy or hypersensitivity to components of the cobimetinib formulationsXx_NEWLINE_xXPatients who have a history of allergy to iodides or iodinated contrast agentsXx_NEWLINE_xXPatients with a known allergy to murine proteins or have had a documented anaphylactic reaction or allergy to any of chemotherapy agents used in this protocol, oregovomab, or to antiemetics appropriate for administration in conjunction with protocol-directed therapyXx_NEWLINE_xXKnown allergy to any of the drugs used in the study. (Subjects who have had a previous allergy to PEG-asparaginase but can receive Erwinia are eligible.)Xx_NEWLINE_xXKnown allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)Xx_NEWLINE_xXKnown allergy attributed to bupropion, varenicline, transdermal or lozenge nicotineXx_NEWLINE_xXAn allergy to iodineXx_NEWLINE_xXKnown allergy or adverse drug reaction to nivolumab, or a history of allergy to study drug componentsXx_NEWLINE_xXKnown or suspected allergy to gemcitabine or MLN8237, or any agent given in the course of this trialXx_NEWLINE_xXKnown or suspected allergy to irinotecan or MLN8237, or any agent given in the course of this trialXx_NEWLINE_xXKnown or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trialXx_NEWLINE_xXHistory of allergy or hypersensitivity to any component of the study drugsXx_NEWLINE_xXKnown allergy to eggs, egg products, aminoglycoside antibiotics (for example, gentamicin or tobramycin)Xx_NEWLINE_xXKnown allergy to eggs, egg products, aminoglycoside antibiotics (for example, gentamicin or tobramycin)Xx_NEWLINE_xXKnown allergy to any of the study medicationsXx_NEWLINE_xXKnown or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trialXx_NEWLINE_xXA known history of allergy or hypersensitivity to any of the study drugs or any of their excipients.Xx_NEWLINE_xXThe patient has a previously-identified allergy or hypersensitivity to components of the study treatment formulationXx_NEWLINE_xXKnown or suspected allergy to gemcitabine or cisplatinXx_NEWLINE_xXHistory of allergy to mannitolXx_NEWLINE_xXA known allergy to any component of the HyperAcute®-Lung immunotherapy or cell lines from which it is derived.Xx_NEWLINE_xXKnown allergy to any of the treatment componentsXx_NEWLINE_xXKnown allergy to bortezomib, boron, or mannitolXx_NEWLINE_xXPatients who have known allergy to mebendazole or benzimidazoleXx_NEWLINE_xXKnown history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib)Xx_NEWLINE_xXKnown allergy to any of the study medications, their analogues, or excipients in the various formulationsXx_NEWLINE_xXThe patient has known allergy to any of the treatment componentsXx_NEWLINE_xXAllergy or hypersensitivity to agents used within the treatment protocolXx_NEWLINE_xXKnown allergy to any of the compounds under investigationXx_NEWLINE_xXHave a known allergy to resiquimod or any of the excipients in the study drugXx_NEWLINE_xXKnown or suspected allergy or hypersensitivity to yeast or any other component of CRS-207 (e.g., glycerol), Platinol or platinum-containing compounds, or pemetrexedXx_NEWLINE_xXThe subject has a previously-identified allergy or hypersensitivity to components of the study treatment formulationXx_NEWLINE_xXMedically diagnosed lactose intolerance, lactose allergy or salicylate allergyXx_NEWLINE_xXAllergy to murine products or positive human anti-mouse antibody (HAMA)Xx_NEWLINE_xXThe participant has a previously identified allergy or hypersensitivity to components of the study treatment formulationXx_NEWLINE_xXKnown allergy to any of the study medications, their analogues, or excipients in the various formulations of any agent.Xx_NEWLINE_xXThe patient requires treatment with corticosteroids at a dose > 0.1 mg/kg/day or has a known allergy to DSMOXx_NEWLINE_xXIf patients meet any of the following they will be excluded:\r\n* Active infection requiring intravenous treatment or having an unexplained febrile illness (temperature maximum [Tmax] > 99.5 Fahrenheit [F]/37.5 Celsius [C])\r\n* Known immunosuppressive disease or known human immunodeficiency virus infection\r\n* Unstable or severe intercurrent medical conditions such as severe heart (New York Heart Association class 3 or 4) or known lung (forced expiratory volume in 1 second [FEV1] < 50%) disease, uncontrolled diabetes mellitus\r\n* Albumin allergy; patients with a known allergy will be excluded\r\n* Gadolinium allergyXx_NEWLINE_xXKnown sensitivity or allergy to murine products.Xx_NEWLINE_xXKnown allergy to any of the study medications, their analogues or excipients in the various formulationsXx_NEWLINE_xXHistory of known allergy or contraindications to the use of pazopanib, paclitaxel, or carboplatinXx_NEWLINE_xXKnown allergy to gadoliniumXx_NEWLINE_xXKnown history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)Xx_NEWLINE_xXKnown or suspected allergy to pazopanibXx_NEWLINE_xX18F FLT CANDIDATE TRANSPLANT RECIPIENT: History of prior fluorothymidine allergy or intoleranceXx_NEWLINE_xXSubjects with known allergy or hypersensitivity to doxorubicin, cyclophosphamide, or eribulin mesylate.Xx_NEWLINE_xXAny contraindication or known allergy or hypersensitivity to any study drugsXx_NEWLINE_xXHistory of allergy to platinum compounds or to antiemetics appropriate for administration in conjunction with protocol-directed chemotherapyXx_NEWLINE_xXKnown history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib).Xx_NEWLINE_xXPatients with a contraindication (e.g. sensitivity/allergy) to trimethoprim/sulfamethoxazole or ampicillinXx_NEWLINE_xXPatient has a known allergy to any component of the study treatment formulationsXx_NEWLINE_xXAllergy to valproic acidXx_NEWLINE_xXKnown or suspected allergy to ARQ 197Xx_NEWLINE_xXAllergy to benzamide or inactive components of entinostatXx_NEWLINE_xXHistory of allergy to study drug componentsXx_NEWLINE_xXPreviously identified allergy or hypersensitivity to components of the study treatment formulations.Xx_NEWLINE_xXKnown allergy to any of the study medications, their analogues, or excipients in the various formulations of any agentXx_NEWLINE_xXPatients with a history of allergy to entinostat or other medications that have a benzamide structure (i.e. tiapride, remoxipride, and clebopride)Xx_NEWLINE_xXHistory of allergy or reaction to any component of the MEDI-551 formulationXx_NEWLINE_xXDONOR: Donors with a known allergy to E. coli-derived products are ineligible for mobilization with G-CSF; alternatives may be used and would have to be discussed individually in these rare circumstancesXx_NEWLINE_xXKnown allergy to allopurinol for subjects assessed with PR following their second-line induction therapy.Xx_NEWLINE_xXPatients with a known allergy to any component of vorinostat, or a known allergy to temozolomide and/or isotretinoin.Xx_NEWLINE_xXKnown or suspected allergy to sorafenib (BAY 43-9006) or any agent given in association with this trialXx_NEWLINE_xXPatients with known allergy to etoposide or a history of grade 3 hemorrhagic cystitis with cyclophosphamide are not eligibleXx_NEWLINE_xXDONOR: Known allergy to filgrastim (G-CSF)Xx_NEWLINE_xXDONOR: Known allergy to G-CSFXx_NEWLINE_xXPatients will be excluded if they have a known allergy to any of the drugs used in the studyXx_NEWLINE_xXHistory of severe allergy to any of the components of NEOD001 such as histidine/L-Histidine, Trehalose, or Polysorbate 20Xx_NEWLINE_xXHas known allergy or history of adverse reaction to ICG, iodine or iodine dyes.Xx_NEWLINE_xXAllergy to measles vaccine or history of severe reaction to prior measles vaccination.Xx_NEWLINE_xXKnown or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trial.Xx_NEWLINE_xXKnown allergy to bone cement,Xx_NEWLINE_xXPatients will be excluded if they have a known allergy to any of the drugs used in the study.Xx_NEWLINE_xXHistory of allergy to study drug components or of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXAny known allergy to the compounds under investigationXx_NEWLINE_xXKnown allergy to any of the study medications, their analogues, or excipients in the various formulations of any agentXx_NEWLINE_xXPatients with known allergy or hypersensitivity to IMGN901Xx_NEWLINE_xXKnown allergy to wheat, rice (contained in the placebo), orange or the sweetener, StevisXx_NEWLINE_xXA known history of allergy or hypersensitivity to any of the study drugs or any of their excipients.Xx_NEWLINE_xXKnown allergy to hyaluronidase or any constituents of docetaxel formulation.Xx_NEWLINE_xXKnown allergy to any of the study medications, their analogues, or excipients in the various formulations of any agentXx_NEWLINE_xXSubject has a history of allergy or hypersensitivity to nab-paclitaxel or gemcitabine or any of their excipients.Xx_NEWLINE_xXKnown or suspected grade 3 allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trialXx_NEWLINE_xXBovine product allergyXx_NEWLINE_xXKnown allergy to any of the study drugsXx_NEWLINE_xXKnown allergy to BCG or MMCXx_NEWLINE_xXKnown or suspected grade 3 allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trialXx_NEWLINE_xXKnown allergy to any of the study medications, their analogues, or excipients in the various formulations of any agentXx_NEWLINE_xXKnown allergy or hypersensitivity to any of the formulation componentsXx_NEWLINE_xXKnown history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)Xx_NEWLINE_xXKnown allergy to any of the study medications, their analogues, or excipients in the various formulations of any agentXx_NEWLINE_xXPrior history of penicillin or streptomycin allergyXx_NEWLINE_xXKnown intolerance or allergy to medications used for sedation (midazolam), analgesia (fentanyl), and local and regional anesthesia (lidocaine, bupivacaine, and ropivacaine)Xx_NEWLINE_xXKnown intolerance or allergy to MR contrast agent (gadolinium chelates) including advanced kidney diseaseXx_NEWLINE_xXPatients with a soy allergy will be excludedXx_NEWLINE_xXKnown allergy or hypersensitivity to any component of the study treatment(s)Xx_NEWLINE_xXHistory of severe allergy or intolerance to contrast agents, narcotics, sedatives or atropine that cannot be managed medicallyXx_NEWLINE_xXKnown or suspected allergy to the investigational agents or any agent given in association with this trial (hypersensitivity reaction, hives, rash, difficulty breathing swelling of your face, lips, tongue, or throat)Xx_NEWLINE_xXPatient has a history of allergy or hypersensitivity to the study drugsXx_NEWLINE_xXHistory of hypersensitivity or allergy to study drugs, aspirin, sulfonamides, or NSAIDsXx_NEWLINE_xXThe subject has a previously identified allergy or hypersensitivity to components of the study treatment formulationXx_NEWLINE_xXThe subject has a known allergy to tetracyclineXx_NEWLINE_xXPatient has a history of allergy or hypersensitivity to the study drugsXx_NEWLINE_xXKnown allergy to macrolide antibioticsXx_NEWLINE_xXKnown allergy to eggs, gentamicin or platinum-containing compoundsXx_NEWLINE_xXKnown allergy to any of the study agentsXx_NEWLINE_xXHistory of allergy to nivolumab componentsXx_NEWLINE_xXAllergy to either of the study medications or 5-fluorouracilXx_NEWLINE_xXKnown or suspected allergy to the investigational agent or any agent given in association with this trial.Xx_NEWLINE_xXNut allergyXx_NEWLINE_xXPatient has a known allergy to bovine or porcine products.Xx_NEWLINE_xXSubject has a previously-identified allergy or hypersensitivity to components of the study treatment formulationXx_NEWLINE_xXAllergy or hypersensitivity to components of either study drug formulationXx_NEWLINE_xXKnown allergy to any study drug or ingredient contained in the drug formulation of any of the study drugs.Xx_NEWLINE_xXAllergy or hypersensitivity to components of the cobimetinib or GDC-0994 formulationXx_NEWLINE_xXKnown history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib)Xx_NEWLINE_xXKnown allergy or history of adverse reaction to ICG, iodine or iodine dyes.Xx_NEWLINE_xXKnown allergy or history of adverse reaction to Blue dye (Isosulfan blue) or triphenylmethane.Xx_NEWLINE_xXHas no known allergy to murine products or positive human anti-mouse antibody (HAMA)Xx_NEWLINE_xXHas no known allergy to murine products or positive HAMAXx_NEWLINE_xXKnown allergy to paclitaxel or any of its componentsXx_NEWLINE_xXHistory of Grade ? 3 allergy to human monoclonal antibodies.Xx_NEWLINE_xXAny contraindication, allergy, or hypersensitivity to rociletinib, trametinib, or excipientsXx_NEWLINE_xXKnown contraindication to intravenous gadolinium contrast administration (e.g., renal impairment, known allergy); standard institutional policies on gadolinium and renal function will be followedXx_NEWLINE_xXKnown allergy to any of the components used during vertebroplasty (polymethyl methacrylate [PMMA] bone cement)Xx_NEWLINE_xXAllergy to implant materials or dental glue.Xx_NEWLINE_xXPatients with known sensitivity or allergy to any components of AMP-224Xx_NEWLINE_xXHistory of severe environmental allergies or allergy to egg proteinsXx_NEWLINE_xXKnown allergy to any of the study drugs or their excipients.Xx_NEWLINE_xXPatient who has a history of allergy or hypersensitivity to any of the study drugsXx_NEWLINE_xXHistory of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies or known sensitivity or allergy to murine productsXx_NEWLINE_xXKnown hypersensitivity/allergy to fluconazole or itraconazole or their respective excipients.Xx_NEWLINE_xXAllergy or hypersensitivity to components of the cobimetinib formulationsXx_NEWLINE_xXDoes the subject have a history of allergy or intolerance to flucytosine?Xx_NEWLINE_xXThe patient has a previously-identified allergy or hypersensitivity to components of the study treatment formulations.Xx_NEWLINE_xXSubjects with a known history of allergy to paclitaxel. Subjects whose allergy was due to the IV solvent (such as Cremophor®) and not paclitaxel will be eligible for this study.Xx_NEWLINE_xXKnown allergy to treatment medication (vemurafenib)Xx_NEWLINE_xXThe subject has a previously identified allergy or hypersensitivity to components of the study treatment formulationXx_NEWLINE_xXKnown allergy or hypersensitivity to any of the test compounds, materials or contraindication to test product.Xx_NEWLINE_xXKnown allergy to study medicationsXx_NEWLINE_xXHistory of significant drug-related allergy (such as anaphylaxis)Xx_NEWLINE_xXKnown history of allergy to Captisol (a cyclodextrin derivative used to solubilize carfilzomib)Xx_NEWLINE_xXPatients with known allergy/hypersensitivity to warfarin or bupropion and/or related compoundsXx_NEWLINE_xXHistory of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies (MAbs, or recombinant antibody-related fusion proteins) or known sensitivity or allergy to murine productsXx_NEWLINE_xXKnown or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients of the formulations given during the course of this trialXx_NEWLINE_xXThe subject has a previously identified allergy or hypersensitivity to components of the study treatment formulationXx_NEWLINE_xXKnown allergy or hypersensitivity to any component of the formulation of CA-4948 used in this studyXx_NEWLINE_xXKnown allergy to doxycycline or other tetracycline antibioticsXx_NEWLINE_xXAllergy to mannitolXx_NEWLINE_xXKnown history of allergy to Captisol(a cyclodextrin derivative used to solubilize carfilzomib).Xx_NEWLINE_xXKnown or suspected allergy or hypersensitivity to any component of TH-302, sorafenib, or any of the sorafenib excipientsXx_NEWLINE_xXHistory of allergy to Urelumab (BMS-663513) or related compoundsXx_NEWLINE_xXHistory of significant drug allergy (such as anaphylaxis or hepatotoxicity) to a prior biologic therapyXx_NEWLINE_xXKnown or suspected hypersensitivity to any component of GVAX Pancreas vaccine or CRS-207, or known allergy to both penicillin and sulfaXx_NEWLINE_xXKnown allergy to any of the study medicationsXx_NEWLINE_xXKnown or suspected allergy to sorafenibXx_NEWLINE_xXThe patient has a known allergy/history of hypersensitivity reaction to any of the treatment components.Xx_NEWLINE_xXKnown or suspected allergy to sorafenib or any agent given in the course of this trialXx_NEWLINE_xXAllergy / history of hypersensitivity reaction to any of the treatment componentsXx_NEWLINE_xXallergy or intolerance to 5-FCXx_NEWLINE_xXKnown history of allergy to Captisol® (a cyclodextrin derivative used to solubilize carfilzomib)Xx_NEWLINE_xXSubject has known sensitivity or allergy to heparinXx_NEWLINE_xXKnown or suspected allergy to any agent given in the course of this trialXx_NEWLINE_xXHistory of allergy or hypersensitivity to nab-paclitaxel, albumin or a taxaneXx_NEWLINE_xXAllergy: known hypersensitivity to other recombinant human antibodiesXx_NEWLINE_xXKnown allergy to eggsXx_NEWLINE_xXKnown allergy or hypersensitivity to KLH, GM-CSF or yeast derived products, or a history of anaphylactic reactions to shellfish proteins.Xx_NEWLINE_xXKnown severe or life-threatening allergy or intolerance to ATG or cyclosporine/ tacrolimusXx_NEWLINE_xXHistory of allergy to study drug componentsXx_NEWLINE_xXPatients with known allergy or hypersensitivity to ponatinib, or 5-azacytidine, or any of their componentsXx_NEWLINE_xXKnown or suspected allergy or hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation of the study drugsXx_NEWLINE_xXPatients with known systemic allergy to bovine or murine productsXx_NEWLINE_xXAllergy to gadoliniumXx_NEWLINE_xXAllergy or hypersensitivity to components of the vemurafenib formulationXx_NEWLINE_xXKnown allergy to any of the agents or their ingredients used in this studyXx_NEWLINE_xXAllergy to bupropionXx_NEWLINE_xXKnown allergy to adhesive tapeXx_NEWLINE_xXKnown or suspected allergy to pamidronate or related productsXx_NEWLINE_xXKnown allergy to EACAXx_NEWLINE_xXAllergy to allopurinolXx_NEWLINE_xXknown allergy to both penicillin and sulfa drugsXx_NEWLINE_xXContraindication or allergy to intravenous lidocaineXx_NEWLINE_xXIs known or suspected to have an allergy to opioids, muscle relaxants or other medications used during general anesthesiaXx_NEWLINE_xXAllergy to egg or egg byproductsXx_NEWLINE_xXWomen with dialysis, chronic urinary infection, hyperthyroidism, current infection, or a history of allergy or sensitivity to iodine will not be eligible to participateXx_NEWLINE_xXKnown history of allergy or intolerance to montelukast, zafirleukast, azithromycin, erythromycin, clarithromycin, prednisone, or sirolimusXx_NEWLINE_xXAllergy to botulinum toxin, and or eggXx_NEWLINE_xXKnown sensitivity or allergy to fish or fish oilXx_NEWLINE_xXFish and/or fish oil allergy or intoleranceXx_NEWLINE_xXMilk allergy excluding lactose intoleranceXx_NEWLINE_xXAllergy or intolerance to bupivacaine or “amide” anestheticsXx_NEWLINE_xXKnown allergy to soy or any soy-based food or supplementXx_NEWLINE_xXKnown allergy to local anestheticsXx_NEWLINE_xXKnown allergy to perampanelXx_NEWLINE_xXKnown allergy to or prior intolerance of aspirin and/or simvastatinXx_NEWLINE_xXHistory of an allergy to romiplostimXx_NEWLINE_xXPatients with known sensitivity or allergy to porcine materialsXx_NEWLINE_xXKnown allergy to the standard of care or ingredients in KeraStat CreamXx_NEWLINE_xXHistory of allergy to fentanylXx_NEWLINE_xXAllergy treatment with antigen injectionsXx_NEWLINE_xXAllergy or adverse reaction to ropivacaine (ropivacaine hydrochloride) or any amide type of local anesthesiaXx_NEWLINE_xXAllergy or adverse reaction to local anesthesia catheterXx_NEWLINE_xXKnown true tape allergyXx_NEWLINE_xXNo known allergy to ingredients of banana bread preparation (eggs, almonds and other nuts since the celery also has almond powder)Xx_NEWLINE_xXKnown allergy to steviaXx_NEWLINE_xXHistory of known allergy to components of the study supplementsXx_NEWLINE_xXAllergy or intolerance to 5HT3 or NK-1 antagonists and dexamethasoneXx_NEWLINE_xXAllergy treatment with antigens injectionsXx_NEWLINE_xXPatients with a known allergy or hypersensitivity to CHG are ineligibleXx_NEWLINE_xXPatients with an allergy to quinolonesXx_NEWLINE_xXContraindication to gadolinium contrast administration during MR imaging, such as allergy or insufficient renal functionXx_NEWLINE_xXPatients must have no known allergy or hypersensitivity to duloxetine or any of the inactive ingredients in the matching placeboXx_NEWLINE_xXKnown allergy to a probiotic preparationXx_NEWLINE_xXFood allergy to any component of the supplementXx_NEWLINE_xXHistory of allergy to investigational agent: ropivacaine or other amino amide analgesicsXx_NEWLINE_xXHistory of allergy to standard agent: propofolXx_NEWLINE_xXAllergy to fentanylXx_NEWLINE_xXAllergy to gabapentinXx_NEWLINE_xXNo known allergy to diphenhydramine, lidocaine, antacid (aluminum hydroxide, magnesium hydroxide, and simethicone), doxepin, tricyclic antidepressants, or any known component of the drug formulation in the testing armsXx_NEWLINE_xXAntibiotic allergy to study medicationXx_NEWLINE_xXAllergy to bone morphogenetic proteinXx_NEWLINE_xXAllergy to bovine collagen productsXx_NEWLINE_xXKnown allergy to both penicillin and trimethoprim/sulfamethoxazole. Participants who are allergic to only one of these antibiotics are allowed to enrollXx_NEWLINE_xXHistory of allergy to study drug component or history of severe hypersensitivity reaction to any monoclonal antibodyXx_NEWLINE_xXPatients with documented allergy to egg products.Xx_NEWLINE_xXPatients with documented allergy to soy products.Xx_NEWLINE_xXKnown allergy to any of the treatment components.Xx_NEWLINE_xXAllergy or hypersensitivity to components of the emactuzumab formulation or to components of the atezolizumab formulationXx_NEWLINE_xXArm C: Patients with a methotrexate allergy are excludedXx_NEWLINE_xXPrevious intolerance/adverse effect/allergy to any component of the placebo or active agentXx_NEWLINE_xXAllergy to beefXx_NEWLINE_xXHistory of allergy to fentanylXx_NEWLINE_xXHistory of allergy to fentanylXx_NEWLINE_xXKnown allergy to heparin or aspirin or a history of heparin induced thrombocytopeniaXx_NEWLINE_xXParticipant has a known allergy to melatonin or any ingredients of the study product or placeboXx_NEWLINE_xXPatients with a history of skin allergy to iodine or adhesive drapesXx_NEWLINE_xXPatients must not have an allergy to latexXx_NEWLINE_xXMajor contraindication to ginseng: allergy/hypersensitivity to Panax species or their constituents (history of arrhythmias, agitation, or motor tics, or severe angina pectoris)Xx_NEWLINE_xXPatients with history of allergy or adverse reactions to sodium bicarbonate or normal salineXx_NEWLINE_xXNo known allergy to either ACE inhibitors or ?-blockersXx_NEWLINE_xXKnown allergy to phenylephrineXx_NEWLINE_xXDoxycycline allergyXx_NEWLINE_xXAllergy to sugar substituteXx_NEWLINE_xXAllergy to gabapentinXx_NEWLINE_xXHave sensitivity or allergy to fish and/or shellfishXx_NEWLINE_xXHave sensitivity or allergy to soy and/or soybeansXx_NEWLINE_xXHypersensitivity/allergy or contraindication to any component of the stent, delivery system, or medication required to complete the procedure,which in the investigator's opinion cannot be adequately premedicatedXx_NEWLINE_xXAllergy or other contraindication to morphine sulfateXx_NEWLINE_xXPatients with allergy, hypersensitivity or other contraindication to dapsone, sulfa antibiotics, or excipients of the dapsone gel productXx_NEWLINE_xXAllergy to either Eucerin or MFXx_NEWLINE_xXKnown allergy or preexisting skin disease which prohibits use of mentholXx_NEWLINE_xXPatients with a history of allergy or adverse reaction to corticosteroidsXx_NEWLINE_xXParticipant has allergy or other contraindication for morphine or gabapentin therapyXx_NEWLINE_xXPrior history of (H/O) severe allergy or asthma requiring active treatmentXx_NEWLINE_xXPatients with a history of allergy to human proteinsXx_NEWLINE_xXKnown allergy to a probiotic preparationXx_NEWLINE_xXAllergy or prior reaction to the fluorescent contrast agent proflavineXx_NEWLINE_xXAllergy or intolerance to gadoliniumXx_NEWLINE_xXAllergy or prior reaction to the fluorescent contrast agent proflavineXx_NEWLINE_xXParticipants who have a known allergy to contrast media.Xx_NEWLINE_xXParticipants who have a known allergy to contrast mediaXx_NEWLINE_xXHistory of allergy to acetic acidXx_NEWLINE_xXNo allergy to finasteride or other five alpha reductase inhibitorsXx_NEWLINE_xXHistory of allergy to apixaban or Factor Xa inhibitorsXx_NEWLINE_xXHistory of any significant drug allergy (such as anaphylaxis or hepatotoxicityXx_NEWLINE_xXDocumented allergy to iron dextran or murine proteinsXx_NEWLINE_xXAllergy to any component of the HPV vaccine including yeast and aluminumXx_NEWLINE_xXKnown allergy to electrode adhesives or woven knit compression fabricsXx_NEWLINE_xXRECIPIENT: Allergy treatment with antigens injectionsXx_NEWLINE_xXHave known hypersensitivity or allergy to eggs, egg or chicken protein, or other components of the study vaccineXx_NEWLINE_xXKnown allergy to LCM or LEVXx_NEWLINE_xXKnown history of allergy to any component or other contraindications to any Neurokinin-1 (NK1) or 5-hydroxytryptamine 3 (5-HT3) receptor antagonists.Xx_NEWLINE_xXIndividuals with a known allergy to lidocaine are not eligibleXx_NEWLINE_xXHistory of allergy or intolerance to ISAXx_NEWLINE_xXPatients with known allergy to boron or boron-containing products, or excipients in the various formulations of any agentXx_NEWLINE_xXHistory of allergy to eggs, egg products, aminoglycoside antibioticsXx_NEWLINE_xXWomen with a known allergy to proflavine, acriflavine, or iodineXx_NEWLINE_xXWomen with an allergy to rapamycin or its derivativesXx_NEWLINE_xXHave a known allergy or food intolerance to ingredients in study products (black raspberries or other berries)Xx_NEWLINE_xXAny known allergy or hypersensitivity to vaginal lubricants or any component of study productXx_NEWLINE_xXDocumented allergy to apixaban and/or enoxaparinXx_NEWLINE_xXAllergy to nicotine patch, nicotine lozenge, or vareniclineXx_NEWLINE_xXKnown sensitivity or allergy to fishXx_NEWLINE_xXPatient has allergy to fish or is a vegetarianXx_NEWLINE_xXPatients who have an allergy to eggsXx_NEWLINE_xXKnown allergy to any of the components of ATIR101 (e.g., dimethyl sulfoxide)Xx_NEWLINE_xXKnown allergy to eggs, egg productsXx_NEWLINE_xXCurrent use of metformin or other anti-diabetic agents, or hypersensitivity or allergy to metforminXx_NEWLINE_xXKnown allergy to any of the components of ATIR101 (e.g., dimethyl sulfoxide)Xx_NEWLINE_xXKnown sensitivity or allergy to turmeric spices or curryXx_NEWLINE_xXBovine product allergy.Xx_NEWLINE_xXSubjects with a known allergy to lidocaineXx_NEWLINE_xXKnown allergy to metformin or other biguanide (Proguanil)Xx_NEWLINE_xXPatients with an allergy to Peridex/chlorhexidine solutionXx_NEWLINE_xXAny serious egg allergy or prior serious adverse reaction to an influenza vaccineXx_NEWLINE_xXHas a history of significant allergy to calcitriol as determined by the investigator.Xx_NEWLINE_xXAllergy to yeast or any of the components of GardasilXx_NEWLINE_xXHas known allergy to Tc99m sestamibiXx_NEWLINE_xXIodide or seafood allergyXx_NEWLINE_xXHistory of allergy to any of the components of OTL38, including folic acidXx_NEWLINE_xXHistory of allergy or hypersensitivity to any component of the treatmentXx_NEWLINE_xXWomen with a known allergy to proflavine or acriflavineXx_NEWLINE_xXSubjects with known hypersensitivity and allergy to ironXx_NEWLINE_xXKnown allergy to adhesive tapes or other skin adhesives used in medical careXx_NEWLINE_xXKnown prior allergic reaction to ICG or allergy to iodineXx_NEWLINE_xXAllergy to sulfa or sulfa-containing medicationsXx_NEWLINE_xXAllergy to sulfa or sulfa-containing medicationsXx_NEWLINE_xXHistory of allergy to iodide drugs or shellfish (iodine allergy)Xx_NEWLINE_xXAny known allergy or prior reaction to fluoresceinXx_NEWLINE_xXPrior history of hypersensitivity to pegylated liposomal doxorubicin or indocyanine green (ICG) allergy; caution should be taken if prior ICG allergy is notedXx_NEWLINE_xXPatients with a contraindication to gadolinium based contrast agents, including allergy or impaired renal function (per UW health guidelines)Xx_NEWLINE_xXWomen with iodine contrast allergyXx_NEWLINE_xXWomen with gadolinium contrast allergyXx_NEWLINE_xXSubjects with contraindications to the use of [18F] FAZA including confirmed allergy.Xx_NEWLINE_xXSubject has an allergy against iodinated contrast agents and cannot be premedicatedXx_NEWLINE_xXAllergy to gadolinium containing contrast mediaXx_NEWLINE_xXHistory of iodinated contrast allergyXx_NEWLINE_xXKnown allergy to FDG or gadolinium based contrast agentsXx_NEWLINE_xXAny known allergy or prior reaction to fluorescein, iodine, or shellfishXx_NEWLINE_xXPatients with a known allergy to BenadrylXx_NEWLINE_xXPatients with a known allergy or hypersensitivity to MRI contrast agents including gadoliniumXx_NEWLINE_xXKnown allergy to gadolinium or the sedative, propofol, used during MRIXx_NEWLINE_xXSubjects with established allergy to IV GBCAXx_NEWLINE_xXPatients with contra-indications to injection of gadolinium contrast; for example patients with prior documented allergy or those with inadequate renal functionXx_NEWLINE_xXPatients with history of allergy to hydrogel dressing or ongoing skin diseasesXx_NEWLINE_xXHistory of serious allergy or reaction to any component of RICE or RDHAP formulations that would prevent administrationXx_NEWLINE_xXPatients with a known allergy to MR contrast agentsXx_NEWLINE_xXHas known allergy to Tc 99m sestamibiXx_NEWLINE_xXParticipants who have a known allergy to contrast mediaXx_NEWLINE_xXHistory of prior fluorothymidine allergy or intoleranceXx_NEWLINE_xXWomen with a known allergy to proflavine or acriflavineXx_NEWLINE_xXPatients with allergy to regadenosonXx_NEWLINE_xXKnown allergy to iodine or intravenous contrast agent.Xx_NEWLINE_xXKnown allergy or anaphylactic reaction to indocyanine green (ICG).Xx_NEWLINE_xXPrevious intravenous (IV) contrast allergyXx_NEWLINE_xXSevere food or medication allergyXx_NEWLINE_xXAllergy to gadolinium or other severe drug allergiesXx_NEWLINE_xXKnown allergy to proflavine or acriflavineXx_NEWLINE_xXPatient with allergy to contrast agentXx_NEWLINE_xXHistory of allergy to iodineXx_NEWLINE_xXHistory of multiple food and/or drug allergyXx_NEWLINE_xXNo known history of allergy to personal care/consumer products or their ingredients, relevant to any ingredients in the test products as determined by the dental/medical professional monitoring the studyXx_NEWLINE_xXHistory of significant adverse effects following use of oral hygiene products such as toothpastes and mouth rinses; allergy to personal care/consumer products or their ingredientsXx_NEWLINE_xXHas a known allergy to dextran or VBD (if intended to be used)Xx_NEWLINE_xXKnown allergy to gadolinium.Xx_NEWLINE_xXPatients with known hypersensitivity or allergy to any component of Sonazoid.Xx_NEWLINE_xXNo allergy to gadoliniumXx_NEWLINE_xXPatients with known hypersensitivity or allergy to any component of DefinityXx_NEWLINE_xXAny known allergy or prior reaction to fluorescein; also, a positive skin prick test to fluorescein is considered an exclusion criteria and the patient would not be eligible for entry into this studyXx_NEWLINE_xXHistory of any anaphylactic reaction, any severe allergy, or any allergy to folateXx_NEWLINE_xXPatients with allergy to iodinated contrastXx_NEWLINE_xXContraindication to use of gadolinium based intravenous contrast, including life threatening allergy or compromised renal function (creatinine > 2.0)Xx_NEWLINE_xXSubjects who have a known allergy to ironXx_NEWLINE_xXHistory of clinically significant sensitivity or allergy to monoclonal antibodies, their excipients, or intravenous gamma globulinXx_NEWLINE_xXKnown hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulationXx_NEWLINE_xXContraindication or allergy to Feraheme (based on insert)Xx_NEWLINE_xXAllergy to fluoresceinXx_NEWLINE_xXAllergy to CT contrast media requiring the administration of steroid prophylaxisXx_NEWLINE_xXAllergy to intravenous CT contrast mediaXx_NEWLINE_xXHas a known allergy to dextranXx_NEWLINE_xXKnown allergy to gadolinium containing contrast agentsXx_NEWLINE_xXKnown allergy to FdCydXx_NEWLINE_xXSubjects with known hypersensitivity and allergy to gadolinium contrast agentsXx_NEWLINE_xXDocumented or reported contrast allergyXx_NEWLINE_xXHave a known allergy to iodinated contrast agentXx_NEWLINE_xXNORMAL VOLUNTEERS: Have a known allergy to iodinated contrast agentXx_NEWLINE_xXHistory of allergic reactions attributed to ICG or other agents used in the study, including known iodide or seafood allergyXx_NEWLINE_xXIodine allergy, hyperthyroidism, or Grave’s diseaseXx_NEWLINE_xXThe patient has a documented intravenous contrast allergy or iodine allergyXx_NEWLINE_xXPatient must not have a history of allergy or bronchial asthmaXx_NEWLINE_xXAllergy to fluoroquinolonesXx_NEWLINE_xXAllergy to any component of sipuleucel-TXx_NEWLINE_xXAllergy to Brussels sproutsXx_NEWLINE_xXParticipants with a known or suspected allergy to iodineXx_NEWLINE_xXKnown allergy to any of the study medications, their analogues, or excipients in the various formulations of any agentXx_NEWLINE_xXKnown allergy or hypersensitivity to monoclonal antibodiesXx_NEWLINE_xXParticipants with aspirin or other NSAIDs-induced asthma or hypersensitivity reaction, sulfonamide allergyXx_NEWLINE_xXNo known sensitivity or allergy to nonsteroidal anti-inflammatory drugs (NSAIDs)Xx_NEWLINE_xXNut or seed allergyXx_NEWLINE_xXAllergy/sensitivity to any study drug (degarelix, enzalutamide, trametinib, dasatinib), or drugs chemically related to study drug, or excipients or to dimethylsulfoxideXx_NEWLINE_xXNo known allergy to tree nutsXx_NEWLINE_xXHistory of allergy to any of the components of OTL38, including folic acidXx_NEWLINE_xXAllergy or hypersensitivity to components of the GDC-0994 formulationXx_NEWLINE_xXHas a known history of hypersensitivity or allergy to pembrolizumab and any of its components and/or to any of the study chemotherapies (e.g., nab-paclitaxel, paclitaxel, gemcitabine, or carboplatin) and any of their components.Xx_NEWLINE_xXKnown hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulationXx_NEWLINE_xXParticipant must not have a history of allergy to erlotinibXx_NEWLINE_xX